MarketPulse

HR+/HER2- breast cancer

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Relay Therapeutics

Relay Therapeutics Advances Breast Cancer Drug Combo Toward Phase 3 Trial

Relay Therapeutics reports positive Phase 2 data for zovegalisib triplet combination in metastatic breast cancer, planning Phase 3 launch in early 2027.
PFERLAYPhase 3 trialzovegalisib
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Prelude Therapeutics' KAT6A Degrader Shows Complete Tumor Regressions in Breast Cancer Models

Prelude Therapeutics shows complete tumor regressions with PRT13722, a first-in-class oral KAT6A degrader, planning IND filing mid-2026 and clinical trials by year-end.
PRLDprecision oncologyHR+/HER2- breast cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Celcuity Inc.

Celcuity's Gedatolisib Shows 76% Risk Reduction in Breast Cancer Trial

Celcuity's gedatolisib achieved 76% risk reduction in advanced breast cancer with PIK3CA wild-type mutations; FDA Priority Review decision expected July 2026.
CELCPhase 3 trialprogression-free survival